Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes were compared with 167 randomly selected, contemporary, age-/sex-matched…

Read the full article here

Source: Blood Cancer Journal

Categories: Hem/Oncs, Latest Headlines

Tags: covid19, COVID19nCancer, IDonc, mmsm

Tweets with this article

Mike Thompson, MD, PhD, FASCO

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality [Oct 19, 2020] Martínez-López et al. BCJ https://t.co/oCxCQ6hM0j #COVID19nCancer #IDonc #mmsm #COVID19 HT @CyclingDoctor

Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19 | mBio

As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma…

Mike Thompson, MD, PhD, FASCO April 20, 2024

Survival in Patients With Hematologic Cancers and COVID-19

This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.

Mike Thompson, MD, PhD, FASCO April 20, 2024

Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials

Click on the article title to read more.

Mike Thompson, MD, PhD, FASCO April 20, 2024

A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA… by Carsten Müller-Tidow

EHA Library; Müller-Tidow C. Jun 10 2022; 357146;

Mike Thompson, MD, PhD, FASCO April 20, 2024

Early Outpatient Treatment for Covid-19 with Convalescent Plasma | NEJM

Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent Plasma

Mike Thompson, MD, PhD, FASCO April 20, 2024

COVID-19 vaccination and breakthrough infections in patients with cancer

Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of…

Mike Thompson, MD, PhD, FASCO April 20, 2024

The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19

Background Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a…

Mike Thompson, MD, PhD, FASCO April 20, 2024

The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study

Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

Mike Thompson, MD, PhD, FASCO April 20, 2024

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of…

Mike Thompson, MD, PhD, FASCO April 20, 2024

Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with…

Mike Thompson, MD, PhD, FASCO April 20, 2024

Related Articles